Source - LSE Regulatory
RNS Number : 4890W
Abingdon Health PLC
23 April 2021
 

 

Grant of Options under SAYE Scheme

 

York, U.K. 23 April 2021:  Abingdon Health (AIM:ABDX) ("Abingdon" or "the Company"), a leading international developer and manufacturer of high quality and effective rapid tests, announces the grant of options to employees under the Abingdon Health plc 2021 Save-as-you-Earn Plan (the "2021 SAYE Scheme").

The 2021 SAYE Scheme is a three year scheme which enables employees to save between £5-£500 per month. Employees who participate in the 2021 SAYE Scheme ("SAYE Participants") are granted  linked options ("SAYE Options") over Ordinary Shares which are exercisable at the end of the savings period.

At the end of the three year saving period the SAYE Participants can elect to either receive SAYE Options or request to be refunded the monies saved. 

All employees of the Company (including executive directors) as at 6th April 2021 (the "Eligible Employees") have been invited to participate in the 2021 SAYE Scheme. SAYE Options have an exercise price of 70 pence per SAYE Option, which represents a 20% discount to the closing mid-market price of 87.5p per Ordinary Share on 22 March 2021, being the trading day before the invitation to Eligible Employees to participate was made.

Other than in the case of a takeover or similar event, SAYE Options will generally only be exercisable by the SAYE Option Holders within the 6 month period following the maturity of his or her related savings contract in April 2024. Any SAYE Options not so exercised within this period will lapse. 

A total of 67 Eligible Employees were granted SAYE Options, over a total of 626,057 Ordinary Shares (representing 0.65% of the Company's current issued share capital).

The following Persons Discharging Managerial Responsibility (PDMRs) have been granted SAYE Options:

PDMR                         Title                                                    Options granted

Chris Yates                 Chief Executive Officer                      25,714

Melanie Ross              Chief Financial Officer                       25,714

Oliver Gardner            Chief Operating Officer                      25,714

 

Following the grant of the SAYE Options there will be outstanding options over 2,381,589 Ordinary Shares in aggregate, representing 2.5% of the Company's issued share capital.

Further details of the Company's Save-as-you-Earn scheme can be found in its admission document date 15 December 2020.

 

- Ends-

 

Enquiries:

Abingdon Health plc



Chris Yates

Chief Executive Officer

Via Consilium

Melanie Ross

Chief Financial Officer


Chris Hand

Non-Executive Chairman





N+1 Singer

Sole Broker and Nominated Adviser

Shaun Dobson, Peter Steel,


Tel: +44 (0) 20 7496 3000

Alex Bond (Corporate Finance)


Tom Salvesen (Corporate Broking)





Consilium

Financial PR

Tel: +44 (0) 203 709 5700

Matthew Neal

abingdonhealth@consilium-comms.com

Mary-Jane Elliott 



Lindsey Neville








 

About Abingdon Health

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

https://www.abingdonhealth.com/



 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Melanie Ross

 

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Abingdon Health plc

b)

 

LEI

 

213800XFI4WV3FBILO20

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 0.025 pence each

 



Identification code

GB00BLF79J41



b)

 

Nature of the transaction

 

 

Grant of Options

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




70 pence

25,714







d)

 

Aggregated information

N/A single transaction



- Aggregated volume




- Price




e)

 

Date of the transaction

 

 

20th April 2021

f)

 

Place of the transaction

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Chris Yates

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Abingdon Health plc

b)

 

LEI

 

213800XFI4WV3FBILO20

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 0.025 pence each

 



Identification code

GB00BLF79J41



b)

 

Nature of the transaction

 

 

Grant of Options

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




70 pence

25,714







d)

 

Aggregated information

N/A single transaction



- Aggregated volume




- Price




e)

 

Date of the transaction

 

 

20th April 2021

f)

 

Place of the transaction

 

Outside a trading venue

 

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Oliver Gardner

 

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Operating Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Abingdon Health plc

b)

 

LEI

 

213800XFI4WV3FBILO20

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 0.025 pence each

 



Identification code

GB00BLF79J41



b)

 

Nature of the transaction

 

 

Grant of Options

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




70 pence

25,714







d)

 

Aggregated information

N/A single transaction



- Aggregated volume




- Price




e)

 

Date of the transaction

 

 

20th April 2021

f)

 

Place of the transaction

 

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSEAFDDEFSEIL
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.